title: Reversal of anticoagulant effects in patients with intracerebral hemorrhage.
abstract: Anticoagulant therapies are increasingly being used for the treatment and prevention of thromboembolic diseases. A growing incidence of anticoagulant-associated intracranial hemorrhage (AICH) has accompanied the rise in their use. Although the rate of intracerebral hemorrhage (ICH) in patients receiving anticoagulation therapies such as heparin and target-specific oral anticoagulants (TSOAs) is significantly lower than that of vitamin K antagonists (VKAs), the mortality rate remains high. TSOAs have only recently become available for use in clinical practice, and presently, there is a paucity of both clinical data and evidence-based guidelines to assist in the management of TSOA-associated intracerebral hemorrhage. In this article, we review current literature and provide physicians with diagnostic and therapeutic considerations for the management of AICH.
authors.affiliation: Division of Transfusion Medicine and Hemostasis, Department of Pathology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.
authors.forename: Sean
authors.initials: S
authors.lastname: Yates
authors.forename: Ravi
authors.initials: R
authors.lastname: Sarode
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002543:Cerebral Hemorrhage / Q000139:chemically induced*; D006801:Humans
chemical_list: D000925:Anticoagulants